ESMO Virtual Advanced Course on Biomarkers for Precision Medicine

Programme

ESMO VIRTUAL ADVANCED COURSE

12-13 NOVEMBER 2020

Co-Chairs
Fabrice André, France
Nicola Normanno, Italy
ESMO VIRTUAL ADVANCED COURSE PROGRAMME
ON BIOMARKERS FOR PRECISION MEDICINE

12-13 November 2020

CO-CHAIRS: Fabrice André, France
             Nicola Normanno, Italy

SPEAKERS:   Reinhard Buettner, Germany
            Rodrigo Dienstmann, Spain
            Federica di Nicolantonio, Italy
            Paul Hofman, France
            Caterina Marchiò, Italy
            Etienne Rouleau, France
            Albrecht Stenzinger, Germany
            Lucy Yates, United Kingdom

LEARNING OBJECTIVES

- An increasing number of therapeutics that require biomarkers testing are available for clinical use or are in advanced phase of clinical development
- Different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
- The increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
- Monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
- The identification of germline variants requires the activation of genetic counselling programs for patients and their families

ACCREDITATION

The programme of this event has been accredited with 6 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Lilly Oncology  MSD
All timings are to be considered CET (Central European Time)

Thursday, 12 November 2020

15:00-15:05 Welcome and introduction
5’ Welcome and Learning Objectives Introduction, Fabrice André, FR and Nicola Normanno, IT

15:05-15:55 Session 1 — NGS comes to the clinic
20’ NGS for tissue biopsies, Reinhard Buettner, DE
20’ Technologies for the analysis of circulating DNA, Nicola Normanno, IT
10’ Discussion

15:55-17:10 Session 2 — New technologies for precision medicine
20’ Gene fusions, Caterina Marchiò, IT
20’ HRD testing, Lucy Yates, UK
20’ Single cell analyses: which impact in cancer research, Fabrice André, FR
15’ Discussion

17:10-17:25 Coffee Break

17:25-18:35 Session 3 — Clinical implementation of NGS
20’ Organization and role of the Molecular Tumour Board, Rodrigo Dienstmann, ES
20’ Incidental findings of NGS testing, Étienne Rouleau, FR
20’ The role of liquid biopsy in monitoring the response to treatment, Federica di Nicolantonio, IT
10’ Discussion

Friday, 13 November 2020

15:00-16:15 Session 4 — Biomarkers for Immune checkpoint inhibitors
20’ Molecular pathology, Paul Hofman, FR
20’ Genomic based assays, Albrecht Stenzinger, DE
20’ Emerging biomarkers, Rodrigo Dienstmann, ES
15’ Discussion

16:15-17:00 Workshop 1 Which patients might benefit comprehensive genomic profiling?
Rodrigo Dienstmann, ES and Fabrice André, FR
15’ Introduction based on clinical cases presented by speakers
30’ Discussion

17:00-17:15 Coffee Break
17:15-18:00

**Workshop 2**

How to integrate liquid biopsy in the management of cancer patients?
Nicola Normanno, IT and Federica di Nicolantonio, IT
15’ Introduction based on clinical cases presented by speakers
30’ Discussion

18:00-18:10

**Synthesis and wrap-up**

---

**ORGANISATION AND CONTACTS**

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org